Found: 32
Select item for more details and to access through your institution.
Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
- Published in:
- Journal of Applied Laboratory Medicine, 2024, v. 9, n. 4, p. 661, doi. 10.1093/jalm/jfae028
- By:
- Publication type:
- Article
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 5, p. 504, doi. 10.1111/ejh.13835
- By:
- Publication type:
- Article
Prescribing of Electronic Activity Monitors in Cardiometabolic Diseases: Qualitative Interview-Based Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.
- Published in:
- Nature Communications, 2016, v. 7, n. 8, p. 12609, doi. 10.1038/ncomms12609
- By:
- Publication type:
- Article
Corrigendum.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 545, doi. 10.1016/j.clml.2022.03.011
- By:
- Publication type:
- Article
Corrigendum to P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) Pages S152-S153]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 424, doi. 10.1016/j.clml.2022.03.009
- By:
- Publication type:
- Article
Corrigendum to "OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT" [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 425, doi. 10.1016/j.clml.2022.03.010
- By:
- Publication type:
- Article
P-217: Isatuximab plus Carfilzomib and Dexamethasone in relapsed Multiple Myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S159, doi. 10.1016/S2152-2650(21)02344-2
- By:
- Publication type:
- Article
P-207: A multi-center, phase 1b study to assess the safety, Pharmacokinetics and efficacy of subcutaneous Isatuximab plus Pomalidomide and Dexamethasone, in patients with Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S152, doi. 10.1016/S2152-2650(21)02334-X
- By:
- Publication type:
- Article
P-137: ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with Lenalidomide and Dexamethasone in high-risk smoldering Multiple Myeloma: safety run-in preliminary results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02264-3
- By:
- Publication type:
- Article
OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
- By:
- Publication type:
- Article
M-Protein semi-quantification in MM serum patients based on Immuno-Capture and Liquid Chromatography coupled to High Resolution Mass Spectrometry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e149, doi. 10.1016/j.clml.2019.09.249
- By:
- Publication type:
- Article
Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e33, doi. 10.1016/j.clml.2019.09.049
- By:
- Publication type:
- Article
Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
- Published in:
- Transfusion, 2022, v. 62, n. 11, p. 2334, doi. 10.1111/trf.17137
- By:
- Publication type:
- Article
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
- Published in:
- Breast Cancer Research & Treatment, 2015, v. 154, n. 2, p. 287, doi. 10.1007/s10549-015-3615-9
- By:
- Publication type:
- Article
The Determinants of Pre- and Postpromotion Dips in Sales of Frequently Purchased Goods.
- Published in:
- Journal of Marketing Research (JMR), 2004, v. 41, n. 3, p. 339, doi. 10.1509/jmkr.41.3.339.35992
- By:
- Publication type:
- Article
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
- By:
- Publication type:
- Article
Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in CombinationWith Erlotinib in Patients With Solid Tumors.
- Published in:
- Oncologist, 2015, v. 20, n. 3, p. 245, doi. 10.1634/theoncologist.2014-0449
- By:
- Publication type:
- Article
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 120, doi. 10.1111/bjh.17499
- By:
- Publication type:
- Article
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
- Published in:
- Cancer Medicine, 2023, v. 12, n. 9, p. 10254, doi. 10.1002/cam4.5753
- By:
- Publication type:
- Article
Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 5, p. 1292, doi. 10.1002/cam4.4478
- By:
- Publication type:
- Article
Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed/refractory multiple myeloma: Long‐term outcomes in the Phase 3 IKEMA study.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 2, p. 1, doi. 10.1002/hon.3258
- By:
- Publication type:
- Article
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
- Published in:
- 2018
- By:
- Publication type:
- journal article
LE WEST EDMONTON MALL: UN ÉCHAFAUDAGE SENSORIEL AU SERVICE D'UNE COSMOGONIE POPULAIRE?
- Published in:
- Revue Française du Marketing, 2004, n. 196, p. 53
- By:
- Publication type:
- Article
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
- Published in:
- Cancer Science, 2020, v. 111, n. 12, p. 4526, doi. 10.1111/cas.14657
- By:
- Publication type:
- Article